CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Frederick Vogt

Interim Chief Executive Officer, President and General Counsel, Iovance Biotherapeutics, Inc.

Search every verified Frederick Vogt interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Frederick Vogt, interim chief executive officer, president, and general counsel of Iovance Biotherapeutics, has been leading the company through its 2025 commercial and pipeline developments. In the second quarter earnings call, he announced a strategic restructuring that included a workforce reduction of approximately 19% in the third quarter of 2025, projected to generate over $100 million in annual cost savings starting in the fourth quarter. He also reported that the company surpassed 100 patients treated with Amtagvi in a single quarter for the first time, citing real-world data showing a nearly 49% response rate among 41 patients. At the annual general meeting in June, Vogt highlighted the company's cash position of $366 million, a cash runway sufficient into the second half of 2026, and projected full-year 2025 burn under $300 million. In the third quarter earnings call, Vogt stated that the company was on track to achieve its full-year 2025 revenue guidance of $250 to $300 million, with expectations for a strong fourth quarter for Amtagvi and increasing Proleukin sales. He discussed ongoing engagement with the FDA regarding the IOV-L122 trial for non-small cell lung cancer, noting confidence in the trial design and patient population but declining to provide specific guidance on trial completion timing. Vogt also expressed that the company was not currently considering partnerships for its TIL technology, citing the complexity of the science and a preference to retain ownership of what he described as potentially powerful future assets.

Recent appearances

  • Iovance Biotherapeutics, Inc IOVA Q3 2025 Earnings Call

    November 24, 2025 · 📺 Fyfull

    --------- Iovance Biotherapeutics, Inc IOVA Q3 2025 Earnings Call --------- In this video, we’ll cover the latest quarterly earnings results, key financial metrics, and business highlights from the most recent reporting period. 🔔 Don’t forget to subscribe and follow us on X for more updates: https://x.com/Fyfull2 Disclaimer: This video includes segments from official corporate earnings calls and presentations, used for educational and informational purposes under fair use (Section 107, U.S. Copyright Act). No affiliation or endorsement by the companies mentioned is implied. All content ri…

    Watch on YouTube ↗

  • Iovance Biotherapeutics IOVA Q2 2025 Earnings Call

    September 23, 2025 · 📺 Fyfull

    --------- Iovance Biotherapeutics IOVA Q2 2025 Earnings Call --------- In this video, we’ll cover the latest quarterly earnings results, key financial metrics, and business highlights from the most recent reporting period. 🔔 Don’t forget to subscribe and follow us on X for more updates: https://x.com/Fyfull2 Disclaimer: This video includes segments from official corporate earnings calls and presentations, used for educational and informational purposes under fair use (Section 107, U.S. Copyright Act). No affiliation or endorsement by the companies mentioned is implied. All content rights r…

    Watch on YouTube ↗

  • Iovance Biotherapeutics (IOVA) AGM 2025 – Full Coverage

    June 11, 2025 · 📺 Fyfull

    Iovance Biotherapeutics (NASDAQ: IOVA) held its 2025 Annual General Meeting on June 10, 2025. Join Interim CEO Fred Vogt for insights on biotechnology, cell therapy advancements, and AGM 2025 proceedings! Explore Iovance’s USD 366M cash position, Amtagvi’s melanoma success, and pipeline progress in lung and endometrial cancers. ⏱️ Timestamps: 00:00 – Iain Dukes, Chairman: Opening Remarks 01:11 – Heather Obie, Inspector: Quorum and Voting Procedures 02:54 – Jean-Marc Bellemin, CFO: Proposal Overview 05:37 – Voting Results 08:29 – Fred Vogt, Interim CEO: Business Presentation 20:25…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →